|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Pathophysiology of colorectal peritoneal carcinomatosis: Role of the peritoneum显示文摘Colorectal cancer(CRC) is the third most common cancer and the fourth most common cause of cancerrelated death worldwide. Besides the lymphatic and haematogenous routes of dissemination,CRC frequently gives rise to transcoelomic spread of tumor cells in the peritoneal cavity,which ultimately leads to peritoneal carcinomatosis(PC). PC is associated with a poor prognosis and bad quality of life for these patients in their terminal stages of disease. A loco-regional treatment modality for PC combining cytoreductive surgery and hyperthermic intraperitoneal peroperative chemotherapy has resulted in promising clinical results. However,this novel approach is associated with significant morbidity and mortality. A comprehensive understanding of the molecular events involved in peritoneal disease spread is paramount in avoiding unnecessary toxicity. The emergence of PC is the result of a molecular crosstalk between cancer cells and host elements,involving several well-defined steps,together known as the peritoneal metastatic cascade. Individual or clumps of tumor cells detach from the primary tumor,gain access to the peritoneal cavity and become susceptible to the regular peritoneal transport. They attach to the distant peritoneum,subsequently invade the subperitoneal space,where angiogenesis sustains proliferation and enables further metastatic growth. These molecular events are not isolated events but rather a continuous and interdependent process. In this manuscript,we review current data regarding the molecular mechanisms underlying the development of colorectal PC,with a special focus on the peritoneum and the role of the surgeon in peritoneal disease spread. | Lieselotte Lemoine Paul Sugarbaker Kurt Van der Speeten | 2016 | World Journal of Gastroenterology2016，22，34： | 12 |
| 2 | Update on the prevention of local recurrence and peritoneal metastases in patients with colorectal cancer显示文摘The prevention of a disease process has always been superior to the treatment of the same disease throughout the history of medicine and surgery.Local recurrence and peritoneal metastases occur in approximately8%of colon cancer patients and 25%of rectal cancer patients and should be prevented.Strategies to prevent colon or rectal cancer local recurrence and peritoneal metastases include cytoreductive surgery and hyperthermic perioperative chemotherapy(HIPEC).These strategies can be used at the time of primary colon or rectal cancer resection if the HIPEC is available.At institutions where HIPEC is not available with the treatment of primary malignancy,a proactive second-look surgery is recommended.Several phaseⅡstudies strongly support the proactive approach.If peritoneal metastases were treated along with the primary colon resection,5-year survival was seen and these results were superior to the results of treatment after peritoneal metastases had developed as recurrence.Also,prophylactic HIPEC improved survival with T3/T4 mucinous or signet ring colon cancers.A second-look has been shown to be effective in two published manuscripts.Unpublished data from MedStar Washington Cancer Institute also produced favorable date.Rectal cancer with peritoneal metastases may not be so effectively treated.There are both credits and debits of this proactive approach.Selection factors should be reviewed by the multidisciplinary team for individualized management of patients with or at high risk for peritoneal metastases. | Paul H Sugarbaker | 2014 | World Journal of Gastroenterology2014，20，28： | 7 |
| 3 | Morbidity and Mortality Analysis of 200 Treatments With Cytoreductive Surgery and Hyperthermic Intraoperative Intraperitoneal Chemotherapy Using the Coliseum Technique显示文摘 | Arvil D. Stephens MD Robert Alderman PA-C David Chang MD Gary D. Edwards PA-C Jesus Esquivel MD Gilbert Sebbag MD Mark A. Steves MD Paul H. Sugarbaker MD | 1999 | Annals of Surgical Oncology1999，，8： | 5 |
| 4 | Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy in the Management of Peritoneal Surface Malignancies of Colonic Origin: A Consensus Statement显示文摘 | J. Esquivel R. Sticca P. Sugarbaker E. Levine T. D. Yan R. Alexander D. Baratti D. Bartlett R. Barone P. Barrios S. Bieligk P. Bretcha-Boix C. K. Chang F. Chu Q. Chu S. Daniel E. Bree M. Deraco L. Dominguez-Parra D. Elias R. Flynn J. Foster A. Garofalo F. | 2007 | Annals of Surgical Oncology2007，，1： | 4 |
| 5 | Pharmacologic rationale for treatments of peritoneal surface malignancy from colorectal cancer显示文摘The peritoneal surfaces of the abdomen and pelvis are important sites for the dissemination of gastrointestinal and gynecologic malignancy. Transcoelomic dissemination of cancer cells gives rise to carcinomatosis, which, without special treatment, is a fatal manifestation of these diseases. To treat peritoneal carcinomatosis, cytoreductive surgery removes gross disease plus perioperative intraperitoneal and perioperative intravenous chemotherapy eradicates microscopic residual disease and chemical compatibilities. Chemotherapy agents are administered either by the intraperitoneal or intravenous route, based on their pharmacologic properties. A peritoneal-plasma barrier, which retards the clearance of high molecular weight chemotherapy from the peritoneal cavity, results in a large exposure of small cancer nodules on abdominal and pelvic surfaces. Tissue penetration of the intraperitoneal chemotherapy is facilitated by moderate hyperthermia (41-42℃). Targeting of intravenous chemotherapy to the peritoneal surface is facilitated by the intraperitoneal heat. A constant dose of chemotherapy agent and volume of carrier solution, based on body surface area, allows prediction of systemic drug exposure and systemic toxicity. Timing of the hyperthermic chemotherapy as a scheduled part of the surgical procedure to uniformly expose all peritoneal surfaces is crucial to success. | PaulH Sugarbaker Kurt Vander Speeten O Anthony Stuart | 2010 | World Journal of Gastrointestinal Oncology2010，2，1： | 4 |
| 6 | Hyperthermic intraperitoneal doxorubicin: pharmacokinetics, metabolism, and tissue distribution in a rat model显示文摘 | Pierre Jacquet Andrew Averbach O. Anthony Stuart David Chang Paul H. Sugarbaker | 1997 | Cancer Chemotherapy and Pharmacology1997，，2： | 4 |
| 7 | Thermal Enhancement of New Chemotherapeutic Agents at Moderate Hyperthermia显示文摘 | Faheez Mohamed MBChB MRCS Pierre Marchettini MD O. Anthony Stuart BS M. Urano MD Paul H. Sugarbaker MD FACS FRCS | 2003 | Annals of Surgical Oncology2003，，4： | 3 |
| 8 | Management of peritoneal-surface malignancy: the surgeon’s role显示文摘 | P. H. Sugarbaker | 1999 | Langenbeck’s Archives of Surgery1999，，6： | 3 |
| 9 | A Systematic Review on the Efficacy of Cytoreductive Surgery and Perioperative Intraperitoneal Chemotherapy for Pseudomyxoma Peritonei显示文摘 | Tristan D. Yan BSc (Med) MBBS Deborah Black BSc DipEd MStat PhD Renaldo Savady MD Paul H. Sugarbaker MD | 2007 | Annals of Surgical Oncology2007，，2： | 2 |
| 10 | Extent of parietal peritonectomy does not change intraperitoneal chemotherapy pharmacokinetics显示文摘 | Vinicius Lima Vazquez O. Anthony Stuart Faheez Mohamed Paul H. Sugarbaker | 2003 | Cancer Chemotherapy and Pharmacology2003，，2： | 2 |
| 11 | Safety monitoring of the coliseum technique for heated intraoperative intraperitoneal chemotherapy with mitomycin C显示文摘 | O. Anthony Stuart BS Arvil D. Stephens BS Laura Welch MD Paul H. Sugarbaker MD | 2002 | Annals of Surgical Oncology2002，，2： | 2 |
| 12 | Treatment of primary colon cancer with peritoneal carcinomatosis显示文摘 | Sophie R. Pestieau M.D. Dr. Paul H. Sugarbaker M.D | 2000 | Diseases of the Colon & Rectum2000，，10： | 2 |
| 13 | Indications for Early Postoperative Intraperitoneal Chemotherapy of Advanced Gastric Cancer: Results of a Prospective Randomized Trial显示文摘 | Wansik Yu Ilwoo Whang Ho Young Chung Andrew Averbach Paul H. Sugarbaker | 2001 | World Journal of Surgery2001，，8： | 2 |
| 14 | Successful management of microscopic residual disease in large bowel cancer显示文摘 | Paul H. Sugarbaker | 1999 | Cancer Chemotherapy and Pharmacology1999，，1： | 2 |
| 15 | Prognostic Indicators for Patients Undergoing Cytoreductive Surgery and Perioperative Intraperitoneal Chemotherapy for Diffuse Malignant Peritoneal Mesothelioma?显示文摘 | Tristan D. Yan BSc (Med) MBBS Erwin A. Brun MD Carlos A. Cerruto MD Namik Haveric MD David Chang MS Paul H. Sugarbaker MD | 2007 | Annals of Surgical Oncology2007，，1： | 2 |
| 16 | Intraperitoneal cancer dissemination: Mechanisms of the patterns of spread显示文摘 | C. Pablo Carmignani Tessa A. Sugarbaker Christina M. Bromley Paul H. Sugarbaker | 2003 | Cancer and Metastasis Reviews2003，，： | 2 |
| 17 | Results of Treatment of 385 Patients With Peritoneal Surface Spread of Appendiceal Malignancy显示文摘 | Paul H. Sugarbaker MD David Chang | 1999 | Annals of Surgical Oncology1999，，8： | 2 |
| 18 | A Systematic Review and Meta-analysis of the Randomized Controlled Trials on Adjuvant Intraperitoneal Chemotherapy for Resectable Gastric Cancer显示文摘 | Tristan D. Yan Deborah Black Paul H. Sugarbaker Jacqui Zhu Yutaka Yonemura George Petrou David L. Morris | 2007 | Annals of Surgical Oncology2007，，10： | 2 |
| 19 | A Clinicopathologic Analysis of 109 Cases with Emphasis on Distinguishing Pathologic Features, Site of Origin, Prognosis, and Relationship to “Pseudomyxoma Peritonei”显示文摘 | Brigite M. Ronnett Christopher M. Zahn Robert J. Kurman Mary E. Kass Paul H. Sugarbaker Barry M. Shmookler | 1995 | The American Journal of Surgical Pathology1995，，12： | 2 |
| 20 | Prevention of Peritoneal Metastases from Colon Cancer in High-Risk Patients: Preliminary Results of Surgery plus Prophylactic HIPEC显示文摘 | Paolo Sammartino Simone Sibio Daniele Biacchi Maurizio Cardi Fabio Accarpio Pietro Mingazzini Maria Sofia Rosati Tommaso Cornali Angelo Di Giorgio Paul H. Sugarbaker | 2012 | Gastroenterology Research and Practice2012，，： | 2 |
您所在的机构暂未开通此部分的功能，请联系管理员